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Background: Prolonged isolated thrombocytopenia (PT) is a frequent complication in patients who undergo
allogeneic hematopoietic stem cell transplantation (allo-HSCT), and it is associated with an adverse prognosis. In this
study, we hypothesized that desialylation on platelet surfaces was associated with PT after allo-HSCT. The mechanisms
participating in this process may include NEU1 translocation, platelet apoptosis, and phagocytosis by macrophages.
Methods: PT was defined as a peripheral platelet count less than 100 × 109/L without sustained anemia or leukopenia
for more than 3 months after allo-HSCT. 34 patients were identified consecutively from a cohort of 255 patients who
underwent allo-HSCT for hematologic malignancies between May and October 2014 at Peking University Institute of
Hematology. Desialylation, enzyme expression, and phagocytosis were detected using flow cytometry,
immunofluorescence, RT-PCR, Western blot, and so on.
Results: Platelets from the PT patients had significantly fewer sialic acids (P = .001) and increased β-galactose
exposure indicative of desialylation on the surface (P = .042), and serum from the PT patients showed a higher
sialic acid concentration (8.400 ± 0.2209 μmol/L, P < .001). The sialidase NEU1 was over-expressed from mRNA to
protein levels, and its catalytic activity was increased in platelets from the PT patients. Desialylation of GPIbα in
the PT patients was correlated with changes in 14-3-3ζ distribution, which, relative to Bad activation, modulated
the expression of Bcl-2 family proteins, depolarized the inner membrane of the mitochondria, and initiated the
intrinsic mitochondria-dependent pathway of apoptosis. Macrophages derived from the THP-1 cell line preferred
to phagocytize desialylated platelets from the PT patients in vitro. We also revealed that oseltamivir (400 μmol/L)
could inhibit 50 % of the sialidase activity on platelets and could protect 20 % of platelets from phagocytosis
in vitro.
Conclusions: Desialylation of platelets was associated with platelet apoptosis and phagocytosis, whereas
oseltamivir could reduce platelet destruction in the periphery, indicating a potential novel treatment for PT after
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Prolonged isolated thrombocytopenia (PT), which is de-
fined as a consistently low platelet count for more than
3 months after transplantation despite the recovery of all
other peripheral blood cell lines, is a frequent complica-
tion of allogeneic hematopoietic stem cell transplant-
ation (allo-HSCT), with an incidence of 5–37 % [1–4].
Previous studies have suggested that poor platelet recov-
ery following allo-HSCT is related to poor overall sur-
vival and has a significant association with III–IV degree
GvHD, resulting in an adverse patient prognosis [3–8].
Although the exact pathogenesis of PT remains un-
known, there are two primary theories as to its origin:
destruction in the peripheral circulation and deficiency
of production in the bone marrow [1, 2, 9, 10]. In the
bone marrow, our previous study found that cellular ele-
ments in the bone marrow microenvironment, including
endothelial cells and perivascular cells, were significantly
reduced in PT patients, indicating that an impaired bone
marrow vascular microenvironment might contribute to
the occurrence of PT [9]. Another of our studies showed
that increased CD8+/CX3CR1+ T cells in the bone mar-
row might also be associated with PT [11]. However, lit-
tle research has explored the increased turnover of
platelets in the peripheral circulation. It has been dem-
onstrated that some morphological platelet indices, such
as the mean platelet volume (MPV), have value for
distinguishing hyperdestructive from hypoproductive
thrombocytopenia [12, 13]. Enlarged MPV can be used
as a measurement of young platelets, indicating that the
origin of thrombocytopenia was peripheral destruction
[13]. Other laboratory methods, such as plasma glycoca-
licin index (GCI), have been reported to be useful for
the diagnosis of thrombocytopenia. Glycocalicin is a
carbohydrate-rich hydrophilic fragment, and the GCI
(plasma glycocalicin level normalized to the individual
platelet count) reflects the rate of platelet destruction
[12]. Previous studies have demonstrated an association be-
tween a high GCI and PT after HSCT [2], indicating in-
creased platelet clearance and turnover in PT pathogenesis.
Our known platelet clearance mechanisms include
antibody-mediated clearance by spleen macrophages, as
observed in immune thrombocytopenia (ITP), and plate-
let consumption due to massive blood loss [14]. How-
ever, the anti-GPIIb/IIIa antibody response failed to
show a necessary association with PT after HSCT via
platelet destruction in the periphery, and some recipi-
ents with PT have neither anti-GPIIb/IIIa antibody
detected nor massive platelet consumption [2]. There-
fore, there must be some antibody-independent platelet
clearance pathogenesis in PT patients. It has been re-
vealed that Fc-independent platelet hepatic clearance
was observed in some ITP patients, especially those with
anti-GPIb/IX antibodies [15–17]. These patients showedpoor responses to steroids and IVIG treatment, indicating
an Fc-independent platelet clearance mechanism [18, 19].
Li et al. reported that platelet desialylation (depletion of
sialic acids) occurred in the presence of anti-GPIbα anti-
bodies, and desialylation of GPIbα occurred directly up-
stream of platelet activation and apoptosis [20]. Moreover,
desialylation of the platelet surface membrane, especially
GPIbα, has been demonstrated to be a key step in the
clearance of chilled platelets after transfusion [21–24].
Sialic acids are monosaccharides with a shared 9-
carbon backbone, and they are typically found at the
outermost end of the glycan chains in all cell types.
Sialic acids play pivotal roles in many physiologically
and pathologically important processes. They play nu-
merous roles in several aspects of immunity, and they
might serve as “self” markers in different physiological
and pathophysiological functions [25–27]. Desialylation
of GPIbα, which is mediated by human sialidase NEU1,
can induce exposure of β-galactose and β-N-acetyl-D-
glucosamine (β-GlcNAc), which can be recognized by
either macrophages or liver cells and can trigger phago-
cytosis of chilled platelets [22, 24, 28, 29].
A prospective cohort study was conducted to determine
whether desialylation of the platelet surface played a role in
the pathogenesis of PT after allo-HSCT. We measured the
sialic acid content and desialylation markers on platelet
surface membranes from PT patients and HSCT recipients
with normal blood cell counts. We also tested sialidase
expression and activity from platelets and analyzed apop-
totic pathways, as well as phagocytosis by macrophages.
Here, we demonstrate that the platelet surfaces were desia-
lylated by NEU1 in PT patients, which was associated with
platelet apoptosis and phagocytosis by macrophages in the
pathogenesis of PT. Moreover, the sialidase inhibitor oselta-
mivir could inhibit NEU1 activity and reduce phagocytosis
of platelets from PT patients in vitro.
Materials and methods
Patients and controls
PT was defined as a peripheral platelet count less than
100 × 109/L without sustained anemia or leukopenia for
more than 3 months after allo-HSCT. Patients were
identified consecutively from a cohort of 255 patients
who underwent allo-HSCT for hematologic malignancies
between May and October 2014 at Peking University In-
stitute of Hematology. Patients with clear causes of
thrombocytopenia were excluded. These causes included
engraftment failure, recurrence of the underlying malig-
nancy, systemic infection, II–IV degree aGvHD, cyto-
megalovirus (CMV) reactivation, and drugs after allo-
HSCT. A total of 34 patients who had developed PT after
allo-HSCT were eligible for our study; 26 allo-HSCT
recipients who had recovered all types of cell counts after
day 90 were extracted as controls from the same cohort.
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as healthy control subjects. All of the samples were col-
lected after the patients provided written informed con-
sent according to the local ethics policy guidelines and the
Declaration of Helsinki.
Transplantation protocols
Pretransplantation conditioning was performed with
cytarabine (4 g/m2 per day, days −10 to −9), busulfan
(3.2 mg/kg per day, intravenously days −8 to −6), cyclo-
phosphamide (1.8 g/m2 per day, days −5 to −4), and
semustine (250 mg/m2, day −3) and either with or with-
out rabbit ATG (thymoglobulin; Imtix Sangstat, Lyon,
France, 1.5 mg/kg per day, days −5 to −2). GvHD
prophylaxis was implemented with cyclosporine A
(CsA), mycophenolate mofetil (MMF), and short-course
methotrexate (MTX) as previously described [30–33].
The effective concentration range of CsA is 150–300 ng/
mL. Oral MMF was administered in doses of 0.5–1.0 g/
day from day −1 to day 30 after transplantation. MTX
was administered i.v. at doses of 15 mg/m2 on day 1 and
10 mg/m2 on days 3, 6, and 11 [30, 31]. Grafts were
granulocyte-colony stimulating factor-mobilized bone
marrow and blood cells as previously described [31, 34].
Oral acyclovir, sulfamethoxazole, and norfloxacin were
administered for infection prophylaxis [32, 35]. Ganciclo-
vir was used from day −9 to day −2 before transplantation
for the prophylaxis of CMV infection [36, 37]. Antifungal
agents were administered as previously described [38].
Bone marrow aspiration and cytogenetic studies were
performed after transplantation to assess engraftment, as
described in our previous studies [1, 9, 31, 34, 39, 40].
Clinical definition and evaluation
Engraftment was demonstrated by increasing neutrophil
and platelet counts unsupported by transfusions. Risk
stratification prior to transplantation was evaluated as
previously described [9, 34]. GvHD was scored as either
acute or chronic based on published criteria [41–43]. A
history of GvHD was defined as patients who were diag-
nosed with either grade II–IV acute GvHD or extensive
chronic GvHD and who required treatment [1, 2, 44].
History of CMV reactivation was defined as either posi-
tive twice for plasma CMV via PCR or a diagnosis of
CMV disease [1].
Platelet sample preparation
Venous blood was obtained from the subjects by
venipuncture and was drawn into 0.1 M citrate-based
anticoagulant (BD Vacutainer). Platelet-rich plasma (PRP)
was prepared by centrifugation at 125×g for 20 min, and
the platelets were separated from PRP by centrifugation
for 5 min at 850×g in a buffer containing 1 μg/mLprostaglandin E1 [28]. Fresh platelets were resuspended at
107/mL.
Measurement of sialic acid residues and glycan exposure
on platelet surface
Platelet surface sialic acid residues and glycan exposure
were evaluated by the binding of fluorescein-labeled
lectins by flow cytometry [22, 24, 29, 45, 46]. The serum
sialic acid concentration and sialidase activity were mea-
sured using ELISA kit (Jrdun Biotech). Desialylation of
GPIbα was confirmed by immunoblot analysis. Sialidase
expression and location were tested by RT-PCR, flow
cytometry, and immunofluorescence. Sialidase activity
assays were performed as previously described [28].
Immunofluorescence and microscopy
The platelets were either fixed in BD Cytofix or fixed
and permeabilized in BD Cytofix/Cytoperm (22 °C,
20 min), followed by centrifugation onto poly-L-lysine-
coated coverslips (500×g for 2.5 min). Cells were blocked
as previously described [47]; the platelets were incubated
overnight with rabbit anti-NEU1 IgG Ab (Santa Cruz
Biotechnology) and then were washed in triplicate with
phosphate-buffered saline (PBS). The washed platelets
were incubated for 1.5 h at room temperature with the
secondary Ab conjugated with either Alexa Fluor 488 or
568 (Molecular Probes) at a dilution of 1:500, followed
by three washes with PBS. Images were obtained as
previously described [28].
Apoptosis assay
Bax and Bcl-xL were measured by flow cytometric ana-
lysis. 14-3-3ζ association was detected by immunoprecipi-
tation. For determination of the mitochondrial membrane
potential (ΔΨm), 100 μL of platelet suspension was incu-
bated with JC-1 (0.5 μM, 30 min, 37 °C). In viable cells, a
high ΔΨm promotes the directional uptake of JC-1 into
the matrix, where JC-1 forms J-aggregates (λex 490 nm,
λem 570–610 nm). In apoptotic cells, a low ΔΨm pre-
serves the monomeric form (λex 490 nm, λem 535 nm).
Changes in the ΔΨm were expressed as the ratio of the
platelets in the lower-right to the upper-right quartile [48].
In vitro phagocytosis assay
THP-1 monocytic cell lines were cultured to a density of
(1–2) × 106/mL in RPMI 1640, glutamine (2 mmol/L),
penicillin (100 U/mL), and streptomycin (100 μg/mL) at
37 °C. Maturation was induced by 500 nmol/L phorbol
myristate acetate (PMA) (24 h at 37 °C). Of platelet
(PLT) suspension, 100 μL was labeled with 1 μmol/L
mepacrine in Hepes-Tyrode (pH 7.2, 5 min, 22 °C).
Mepacrine-labeled PLTs (107/well) that were previously
subjected to different treatments were added to the
phagocytes in Ca2+- and Mg2+-containing HBSS (GIBCO
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binding of PLTs to macrophages was expressed as the
percentage of CD42b/CD14-positive particles to the total
number of CD42b- and/or CD14-positive particles.
Phagocytosis of PLTs by macrophages was measured by
FACS analysis of mepacrine-positive CD14 cells that
were inaccessible to the CD42b antibody, and it is
expressed as the percentage of the total number of
CD14-positive/CD42b-negative particles [49–51].Statistical analysis
All of the data are presented as the means ± SEMs unless
otherwise indicated. All numeric data were analyzed for
statistical significance by non-paired Student’s t test
(unless otherwise specified) for multiple comparisons,
using Prism software (GraphPad). P < .05 was considered
statistically significant.Table 1 Clinical characteristics of the patients after HSCT with PT
Characteristics PT cases
Time of evaluation (post-HSCT) 100 (80–1
Age at HSCT, median (range), year 27 (11–56
Gender (male/female) 22/12




Source of stem cell
BM and PB 29
PB 5
Transplanted total nucleated cell dose, ×108/kg 7.195 (5.0
Transplanted CD34+ cells, ×106/kg 1.925 (0.7
Donor type







BU/CY + ATG 27
BU/CY 4
TBI 3
History of severe GvHD 21
History of CMV reactivation 26
aThe continuous variables were compared using the one-way ANOVA, and the diffe
Chi-square testResults
Patient characteristics
We identified 34 consecutive patients with PT, whereas the
comparison cohort consisted of 26 subjects after allo-HSCT.
The patient characteristics are summarized in Table 1. All
of the characteristics, except a history of CMV reactivation
and a history of GvHD, were nearly equally represented.
A larger proportion of the PT patients had a history of
grades II to IV acute GvHD or extensive chronic GvHD
after transplantation (P = .021). Additionally, more allo-
HSCT recipients with PT had experienced CMV reacti-
vation from the day when they accepted the donors’
stem cells (P = .029).
There were no significant differences between the pa-
tients with PT and the controls (P > .05) with regard to the
demographic and clinical characteristics, including age, sex,
underlying disease, disease status before transplantation,
donor types, source of stem cells, transplanted total(n = 34) Controls (n = 26) P valuea
50) 121 (87–149) .078
) 26 (3–58) .959
15/11 .603





0–10.10) 6.905 (3.44–9.12) .350











rences in frequency between the two groups were compared using the
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history of GvHD, history of CMV reactivation, and anti-
CMV therapy (Table 1).
Patients with PT have higher MPV and increased GCI
To confirm that hyperdestruction in the peripheral
blood was involved in the pathogenesis of PT, we mea-
sured the MPV and GCI of the PT patients and the con-
trol recipients. MPV was significantly higher in the PT
patients (9.82 ± 1.31 vs. 8.41 ± 1. 54, P < .001), and an in-
verse correlation between platelet count and MPV value
was demonstrated (ρ < 0.001, r = −0.56, Spearman’s rank
correlation rho) (Fig. 1a, b). To evaluate further the
platelet turnover, we calculated the GCI of the PT
patients. GCI was markedly increased in the PT patients,
compared to the control group (5.56 ± 2.68 vs. 3.06 ±
1.78, P < .001) (Fig. 1c). Taken together, the PT patientsFig. 1 Platelets from PT patients showed hyperdestruction. a Histogram of
correlation between MPV and PLT count. c Histogram of GCI. d The inversehad significantly higher MPV and increased GCI, also in-
dicating elevated platelet destruction.
Platelets from patients with PT have higher desialylation
levels
Sialic acid moieties were detected by flow cytometry
using a panel of lectins (Fig. 2a). In this study, the
platelets from the PT patients showed significantly
lower levels (P = .001) of binding to Sambucus nigra lec-
tin (SNA), which is a lectin specific for the α2,6-sialic acid
residues on the platelet membrane. However, the α2,3-si-
alic acid residues, measured by Maackia Amurensis lectin
(MAL), showed no difference between the patient and
control groups (P = .227).
With regard to desialylation markers, we observed that
the β-galactose exposure levels were higher on the PT
patient platelet surfaces, as detected by RCA-I (P = .042,MPV. MPV was significantly higher in PT patients. b The inverse
correlation between GCI and PLT counts
Fig. 2 Sialic acid residues on platelet surfaces and in plasma. Lectin binding to fresh platelets was tested in the presence or in the absence of
10 mU of α2-3,6,8,9-sialidase from A ureafacients (Neu treated). a Flow cytometry analysis of sialic acid residues on platelet surfaces, as detected
by FITC-labeled SNA or MAL. b β-galactose and β-GicNAc exposure on platelet surface glycoprotein, as detected with FITC-labeled RCA-I or
succinyl-wheat germ agglutinin (sWGA), respectively. c Typical graph of flow cytometry analysis of platelet surface α2,6-sialic acid (α2,6-SA).
d Serum sialic acid concentration measured by ELISA
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showed no significant differences between the PT pa-
tient and control groups (P = .063).
The sialic acid concentration in the serum (Fig. 2c)
from the patients with PT was higher than in the
control group (8.400 ± 0.2209 μmol/L vs. 5.579 ±
0.4219 μmol/L, respectively, P < .001), but both concen-
tration levels were higher than those of the healthy vol-
unteers (0.8660 ± 0.3251 μmol/L, N = 10).
GPIbα is the primary glycoprotein that is desialylated on
the platelet membrane
We investigated the glycoprotein that was the primary
substrate that was desialylated and that exposed β-
galactose residues. Immunoblotting of desialylated plate-
let lysates from the PT patients using RCA-I binding
showed multiple glycoproteins with exposed β-galactose
residues. Two major desialylated proteins were shown,
one of which had an apparent molecular weight of
140 kDa, a size consistent with GPIbα, which was con-
firmed by probing the lysates with a specific antibody.
The other protein of 240 kDa was identified as aplatelet-bound von Willebrand factor (vWF) (Additional
file 1: Figure S2).
Human sialidase NEU1 is over-expressed on the platelet
surface
To elucidate further the mechanism of desialylation, the ex-
pression of human sialidases, NEU1, NEU2, NEU3, and
NEU4 was measured in the platelets from the PT patients.
Sialidase expression was tested using flow cytometry, quan-
titative PCR (qPCR), and immunofluorescence microscopy.
A real-time qPCR approach was adopted to detect mRNA
for the four types of sialidases, and the data were normalized
to HPRT mRNA in the same sample. NEU1 mRNA was
significantly higher in platelets from the PT patients (4.212
± 2.872 copies vs. 1.301 ± 0.678 copies, P = .049, Fig. 3a).
NEU1 expression was significantly higher (P = .002) on
the membrane of the platelets from the control group as
measured by flow cytometry and immunofluorescence,
and its distribution was similar to that of the ECL binding
experiments (Fig. 3b, c). We also observed a positive
correlation between the increased levels of RCA-I binding
and NEU1 surface expression (Spearman’s correlation ρ =
Fig. 3 (See legend on next page.)
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Fig. 3 Sialidase expression and activity. a Total RNA isolated from platelets was reverse-transcribed, and the resulting cDNA was used as a template for
amplification with primers corresponding to NEU1, NEU2, NEU3, and NEU4, as well as HPRT as a housekeeping gene control. The mRNA level for each
sialidase was normalized to HPRT. b Flow cytometry analysis of NEU1 and NEU3 expression on platelet surfaces. The data are presented as MFI. c NEU1
localization in the platelets from the patients and the control group. The fluorescence intensity of NEU1 in the PT platelets was slightly elevated after
permeabilization, and its distribution was correlated with that of β-Gal. The NEU1 signals of the platelets from the control group were weaker than
those from the PT patients, especially when not permeabilized. d Correlation between the increase in RCA-I and NEU1 expression in the PT patients.
R2 = 0.408. Correlation between NEU1 and RVA-I MFI was determined by Spearman’s correlation coefficient; P = .585, P = .17. e Sialidase activity inside
and on the surfaces of platelets from the PT patients. The total sialidase activity in platelets was measured after detergent permeabilization. f Total
NEU1 expression of the platelets from the PT patients and the control group
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measured after detergent permeabilization, which indi-
cated that NEU1 translocated from the cytoplasm to the
platelet surface (Fig. 3c).
A catalytic activity assay showed that platelets from
the control group had little surface sialidase activity to-
ward 4-MU-NeuAc, but this activity could be detected
on the platelet surface from the PT patients. The total
sialidase activity was higher in the platelets from the PT
patients (Fig. 3e). All of these results suggested that
NEU1 was responsible, at least partially, for the increased
sialidase activity on the outer membrane of the platelets
from the PT patients, and it induced desialylation of theFig. 4 Platelets from the PT patients showed higher apoptosis. a Histogram o
lower-right quartile to those in the upper-right quartile. b ΔΨm as a measure
GPIbα, measured by immunoprecipitation. d Activated Bad, Bax, and Bcl-xL w
control groupplatelet surface. Measurement of total sialidase activity after
permeabilization indicated that NEU1 was not only over-
expressed but was also released on the platelet surface.
We detected little sialidase activity in the blood serum
from either the patients or the control group (Additional
file 1: Figure S2).
GPIbα desialylation is associated with increasing
apoptosis of platelets
To investigate the clearance mechanism of the platelets
in the peripheral blood, we analyzed the apoptosis of the
platelets. The platelets were incubated with JC-1 dye to
detect the depolarization of the inner mitochondrialf ΔΨm. The data are expressed as the ratio of fluorescent platelets in the
ment of JC-1 binding using flow cytometry. c 14-3-3ζ, associated with
ere analyzed by flow cytometry in platelets from the PT patients and the
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pathway initiation. Platelets from the PT patients showed
a remarkably larger ΔΨm than in the control group
(2.992 ± 0.2753 vs. 0.7764 ± 0.1121, P= .028) (Fig. 4a), indi-
cating an increase in intrinsic apoptosis (Fig. 4a). A correl-
ation between the increased levels of RCA-I binding and
elevated ΔΨm was also observed (Spearman’s correlation
ρ = 0.585, P = .017).
To investigate whether the increase in apoptosis initi-
ation was associated with GPIbα desialylation, we mea-
sured GPIbα association with 14-3-3ζ proteins. The
platelets from the PT patients exhibited an approxi-
mately sixfold higher association rate between GPIbα
and 14-3-3ζ, compared to the platelets from the control
group (635 ± 45.23 % of the control, P < .001) (Fig. 4c).
Moreover, analysis of Bad confirmed that loss of this as-
sociation increased the dephosphorylation of Bad. To
confirm that Bad dephosphorylation played a role in this
procedure, two Bcl-2 family members were investigated.
Flow cytometric analysis with antibodies against the ac-
tive epitope of Bax and the active conformation of Bcl-
xL revealed that Bax and Bcl-xL changed in parallel with
the phosphorylation of Bad (Fig. 4d). Platelets from the
PT patients showed a twofold increase in active BaxFig. 5 In vitro phagocytosis of platelets and the influence of oseltamivir. St
b Patients’ response. c Phagocytosis rates of the PT patients, HSCT controls
treated with Neu to provide a positive control. d Effects of different concen
e Effects of different concentrations of oseltamivir on the phagocytosis of p
phagocytosis of platelets. The concentration of DANA is 1 mmol/L(P = .027) and a tendency toward reduction in active
Bcl-xL (P = .059).
Macrophages prefer to phagocytize desialylated platelets
from patients with PT in vitro
Next, we analyzed the phagocytosis of the platelets in vitro
to investigate further the clearance mechanism. Macro-
phages were differentiated from THP-1 cells by stimulating
them with PMA. The platelets from the PT patients exhib-
ited a twofold increase in the phagocytosis ratio, compared
to platelets from the control group (P = .045; Fig. 5c). Con-
sistent with the platelets from the patients, desialylated nor-
mal platelets that were incubated with 10 mU of Neu
showed an even higher phagocytosis ratio (12.4 ± 0.55 %,
Fig. 5c). This process could be inhibited by 2,3-didehydro-
2-deoxy-N-acetylneuraminic acid (DANA) (P < .05).
Risk factors for PT
In the univariate logistic regression, a history of GvHD,
CMV reactivation after allo-HSCT, and decreased SNA
binding were associated with PT (P < .10). In the multi-
variate logistic regression analysis, the MFI of SNA bind-
ing (odds ratio [OR], 8.137; 95 % confidence interval
[CI], 2.364 to 28.005; P = .001) and a history of GvHDimulated THP-1 cells were incubated with platelets. a Control response.
, and PT patients with DANA. Platelets from the healthy controls were
trations of oseltamivir on sialidase activity on the platelet surface.
latelets. f Effects of different concentrations of dexamethasone on the
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as the primary independent risk factors for PT (Table 2).
There was no association found between a history of
GvHD and SNA binding in this study.
Oseltamivir decreased the phagocytosis of desialylated
platelets by macrophages
Because we identified the involvement of the sialidase
NEU1 in the pathogenesis of PT, we hypothesized that
the sialidase inhibitor oseltamivir might inhibit NEU1
activity and reduce the clearance of platelets. To confirm
our hypothesis, oseltamivir was added to the sialidase
activity assay and phagocytosis assay. In the sialidase
activity assay, oseltamivir at different concentrations
(100 μM, 200 μM, 400 μM and 1 mM) induced a de-
crease in sialidase activity on the PT platelet surfaces in
a dose-dependent manner (Fig. 5d). The difference was
significant (P < .05) when the concentration of oseltami-
vir was greater than 200 μM, and the inhibition rate was
33 % at 400 μM. These data were consistent with the re-
sults using DANA. In the phagocytosis assay, oseltamivir
treatment reduced the rate of platelet phagocytosis in a
dose-dependent manner after 30 min of incubation (Fig. 5e).
The difference was significant (P < .05) when the concen-
tration of oseltamivir was greater than 400 μM, protecting





OR 95 % Cl P
value**
Demographics
Gender, female vs. male .580
Age, per decade .103
Disease characteristics




Donor type, PMRD vs. others .246





History of severe GvHD .017 4.056 1.171–
14.050
.027
CMV infection after HSCT .016
Desialylation levels
MFI of SNAa <.001 8.137 2.364–
28.005
.001
Abbreviations: OR odds ratio, CI confidence interval, HSCT hematopoietic stem
cell transplantation, PT prolonged isolated thrombocytopenia, PMRD partially
matched related donor, GvHD graft-versus-host disease, CMV cytomegalovirus
*P < .10 in univariate analysis; **P < .05 in multivariate analysis
aThe MFI of SNA was separated into 2 groups according to the receiver
operating characteristic (ROC) cutoff point (23.5)Because PT shares some similarities with immune
thrombocytopenia, corticosteroids such as dexametha-
sone have been administered to treat PT after transplant-
ation, according to therapy for ITP. Therefore, we used
dexamethasone for treatment comparison. The results
showed a dose-dependent reduction in the phagocytosis
ratio of platelets with different concentrations of dexa-
methasone (Fig. 5f ). However, this difference was not
statistically significant.
Discussion
Our results indicated for the first time that desialylation
contributed to the pathogenesis of PT after transplant-
ation and suggested two possible mechanisms (apoptosis
and phagocytosis) by which desialylation contributes to
the pathogenesis of PT. We also observed that oseltami-
vir could inhibit the catalytic activity of sialidase on the
platelet surface and could reduce the phagocytosis of
platelets by macrophages.
PT has been reported to be associated with an in-
creased risk of bleeding [52], and it has been related to
life-threatening complications and poor overall survival
[2]. Several risk factors, including the source of stem
cells, the CD34+ cell count, disease status, GvHD, CMV
infection, and the bone marrow vascular microenviron-
ment, have been proposed to be associated with PT after
allo-HSCT [1, 2, 5, 9, 53]. By multivariate analysis, we
found that a history of GvHD was an independent risk
factor for PT after allo-HSCT. However, after the exclu-
sion of patients with causes described above, there were
still some PT patients showing no direct cause of
thrombocytopenia. We previously found that PT after
allo-HSCT might be related to defects in megakaryocyte
maturation, probably due to an impaired bone marrow
immune and vascular microenvironment [1, 9, 11]. How-
ever, the disruption of the bone marrow environment
cannot explain the clinical manifestations by which some
PT patients showed similar presentations to ITP pa-
tients, such as abnormalities in T cells mediated immun-
ity [54]. Moreover, there was evidence demonstrating
that increased platelet turnover played a role in the
pathogenesis of PT [2]. Elevated platelet turnover could
be found in these patients, including increased MPV and
GCI [2]. Allo- or autoantibodies against platelets can ob-
viously accelerate the destruction of platelets, which is
the main pathogenesis of ITP [55]. However, recipients
after allo-HSCT have different characteristics from non-
transplant patients with thrombocytopenia, including
ITP, because immune reconstitution has not been ac-
complished [56], and most of the recipients received
strong immune suppression therapy (CsA, MMF, gluco-
corticoids, or anti-CD20/CD25 monoclonal antibodies).
Due to allo-HSCT itself and immunosuppression therapy
after transplantation, the main lymphocyte populations
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B cells) required 4 to 6 years post-transplantation to re-
turn to age-matched control levels, with absolute numbers
of B cells increasing gradually and reaching normal levels
more than 1 year after HSCT [56, 57]. Therefore, the pro-
duction of antibodies was strongly inhibited when samples
were collected in this study [57]. Some anti-CMV anti-
bodies can increase the platelet turnover, as previously
described [58, 59], but the positive rate of CMV antibody
was obviously lower than that of DNA quantified by PCR
and of pp65 antigen detected by FCM [60]. Thus, it needs
to be elucidated whether anti-platelet antibodies partici-
pate in the occurrence of PT after allo-HSCT, like they do
in the pathogenesis of ITP. A previous study found no
association between anti-platelet antibody response and
PT after allo-HSCT [2]. Therefore, we hypothesized that
some antibody-independent platelet clearance participated
in the pathogenesis of PT, such as the loss of sialic acids
found in cooled platelets.
Because sialic acids can act as “self-associated molecu-
lar patterns” (SAMPs) and inhibit immune activation
[27], desialylation can induce the activation of innate im-
mune cells and lymphocytes, as well as trigger the
phagocytosis of proteins and cells [20, 27, 45, 61]. Desia-
lylation is known to lead to the sequestration of platelets
from the blood by the reticuloendothelial system, and it
has been correlated with a reduction in the platelet life
span [62, 63]. It has been demonstrated to be a key step in
the clearance of transfused refrigerated platelets [21, 28],
and it also plays a role in the pathogenesis of
thrombocytopenia during sepsis and in some parasitic
infections [62, 64]. Consistent with these findings, our
data showed that desialylation also participated in the
pathogenesis of PT after transplantation.
The significantly higher concentration of sialic acid
levels in the serum of PT patients might not only be at-
tributed to platelet desialylation but might also result
from inflammatory conditions or vascular damage, be-
cause both the patient and control groups showed
higher levels than the healthy control group. Although
platelets are one of the sources of sialic acids [65, 66],
glycoproteins and other cellular components in the per-
ipheral blood or from tissue can be desialylated, leading
to elevated sialic acid concentration in plasma [27].
Serum sialic acids have been demonstrated to be a gen-
eral indication of the “acute phase response” and related
to vascular damage in patients with diabetes and cardio-
vascular disease [25, 67]. The higher sialic acids in the
plasma of HSCT recipients than in the healthy controls
could be attributed to HSCT therapy and complications,
because most recipients of allo-HSCT experience condi-
tioning regimens with high-dose chemotherapy, engraft-
ment of donor cells, and possibly aGvHD, TMA,
infections, and drugs [30, 34].Tracing the enhanced desialylation to the platelet surface
plasma membrane, we detected elevated sialidase activity
on platelets from the PT patients, whereas the serum si-
alidase activity was undetectable in all of the groups in our
study (Additional file 1: Figure S1), and platelets from the
control group showed little sialidase activity on the surface.
This finding suggested that desialylation was not mediated
by serum neuraminidase from pathogens.
In human tissues, NEU1 generally exhibits the stron-
gest expression of the human neuraminidases (10–20
times greater than those of NEU3 and NEU4) [68], and
our data from the platelets were consistent with this.
We detected surface over-expression of NEU1 in the PT
patients with platelet desialylation, supporting the hy-
pothesis that desialylation of platelets is caused by NEU1
over-expression on platelet surfaces and not by exogen-
ous neuraminidases from pathogens.
Although NEU1 is typically located in the lysosomes,
recent studies have revealed the subcellular localization of
NEU1 sialidase to the plasma membrane as well as within
lysosomes under conditions of cell stimulation [69], allow-
ing NEU1 to desialylate glycoproteins on the cell surface
or in the extracellular environment [70]. On the platelet
surface, NEU1 expression is elevated after refrigeration,
and it desialylates platelet surface glycoprotein, leading to
platelet clearance from the peripheral blood [28].
GPIbα is a membrane protein highly glycosylated with
plenty of sialic acid residues at the end of its glycan
chains. Desialylation of GPIbα could induce clustering
and might result in the redistribution of 14-3-3ζ in the
cytoplasm and apoptosis initiation [48, 71].
Platelet apoptosis has been reported in a number of phys-
ical and pathological settings, including chemical stimuli,
high shear stress, ITP pathogenesis, and Helicobacter pylori
bacterial infection [72]. The intrinsic mitochondria-
dependent pathway of apoptosis in the platelets has been
well documented, and a number of key parameters of the
intrinsic pathway of apoptosis have been induced in the
platelets in response to different triggers, including ΔΨm
depolarization; the expression, activation, and translocation
of pro-apoptotic Bax, Bak, and Bid to the mitochondria; the
release of cytochrome c into the cytosol; and the activation
of caspase-9 [72].
GPIbα is associated with 14-3-3ζ proteins, which in
addition to contributing to GPIbα signaling via phos-
phatidylinositol 3-kinase (PI3K) during vWF ligation,
also control the dephosphorylation of Bad, an upstream
element in the intrinsic apoptosis pathway. 14-3-3ζ se-
questers cytosolic Bad, thereby protecting its phosphor-
ylated, dormant state against activation [48, 73, 74].
Because the association of 14-3-3ζ with GPIbα might dis-
turb its association with Bad and induce apoptosis, we first
investigated apoptosis in the platelets from the PT pa-
tients, and we speculated that there were associations
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distribution, and apoptosis. We clarified that the apoptotic
markers along the intrinsic pathway were present in differ-
ent profiles in the PT patients compared to the HSCT
control group, indicating an increase in apoptosis. This
change was related to the redistribution of 14-3-3ζ, indi-
cating an association between desialylation and enhanced
apoptosis.
Desialylation exposes β-galactose and β-GlcNAc at
the end of the glycan chains, which could be recognized
by their corresponding receptors on liver cells and mac-
rophages, respectively [24, 29]. These receptors, also
called lectins, are carbohydrate-binding proteins con-
taining a carbohydrate recognition domain (CRD) that
binds with high specificity to the outermost sugars of
glycans, as well as glycosphingolipids [23]. Mac-1 (CR3,
αMβ2; CD11b/CD18) is a β2 integrin expressed by
macrophages, and previous studies have shown that
desialylated and clustered GPIbα on chilled platelets
was the counter-receptor for Mac-1, leading to their
clearance by phagocytosis [24, 49].
Our data showed an increased phagocytosis ratio of
platelets from the PT patients, whereas DANA could
diminish phagocytosis, which indicated that desialylation
occurred continuously in the circulation and sialidase
inhibitor could help to reduce desialylation in vitro. How-
ever, it has also been reported that desialylation led to
phagocytosis by liver cells via Ashwell receptors in chilled
platelets [29] although whether a similar mechanism is
involved in PT pathogenesis remains to be determined.
We surmised that if desialylation was associated with
platelet apoptosis and phagocytosis, sialidase inhibitors
might diminish platelet clearance and facilitate platelet
survival. Thus, we treated the samples with oseltamivir
and found that it could also inhibit human sialidase ac-
tivity and reduce the phagocytosis of platelets in vitro.
Our data demonstrated that oseltamivir could also in-
hibit human sialidase activity. Upon addition to the
phagocytosis test system, oseltamivir also showed inhib-
ition of phagocytosis. The effect of oseltamivir on the
phagocytosis of platelets from the control group was un-
known, but because few platelets from the control group
were consumed by the phagocytes, this uncertainty did
not affect our conclusion that oseltamivir could amelior-
ate the phagocytosis of platelets from PT patients. This
observation indicated a novel strategy for the manage-
ment of PT after allo-HSCT, because oseltamivir can be
administered to PT patients who show no reaction to
corticosteroids. Moreover, because NEU1 expression in-
dicated an antibody-independent platelet clearance
mechanism, which is a condition under which corticoids
might not work well, it could be speculated that NEU1
over-expression in PT patients might be associated with
resistance to corticoids, and these patients might benefitfrom sialidase inhibitors, such as oseltamivir. Because
the specific target of oseltamivir was not verified in this
study, further effort should be undertaken to investigate
the sialidase that is inhibited by oseltamivir, because in
this study, it was oseltamivir itself that exhibited the in-
hibition and not oseltamivir carboxylate, which is the
main metabolized form. Previous studies have shown
that oseltamivir could inhibit NEU1 and could impede
human pancreatic cancer growth [75]. Hata et al. re-
ported that oseltamivir carboxylate scarcely affected the
activities of any of the sialidases [76].
Post-transplant thrombocytopenia is frequently caused
by multiple factors, and it is frequently difficult to deter-
mine the exact cause of thrombocytopenia after allo-
HSCT, such as infection, GvHD, drugs, impaired bone
marrow microenvironment, and desialylation. The pa-
tients with desialylated platelets in this study showed no
explicit cause of thrombocytopenia, and they exhibited
elevated platelet turnover. Some patients might share
similar characteristics to patients with ITP, such as T cell
abnormalities [54, 77].
The present study demonstrated that desialylation on
the platelet surface was significantly higher in patients
with PT after allo-HSCT. Both NEU1 expression and
activity on the platelet surface were significantly elevated
in the PT patients. Furthermore, our data indicated that
platelet desialylation played a role in PT pathogenesis
because desialylation was correlated with increased
platelet apoptosis and phagocytosis. It was shown that
oseltamivir could inhibit the desialylation activity on the
platelet surface and subsequently decrease the phagocyt-
osis of platelets, indicating a novel candidate strategy for
the management of PT after allo-HSCT.
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